![]() |
市场调查报告书
商品编码
1297797
全球细胞分拣市场 - 2023-2030年Global Cell Sorting Market - 2023-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
全球细胞分拣市场在2022年达到2.365亿美元,预计到2030年将见证有利可图的增长,达到3.898亿美元。在2023-2030年的预测期间,全球细胞分拣市场预计将呈现6.6%的复合增长率。
细胞分选在研究、临床诊断和治疗方面有许多应用。它使分离稀有细胞群成为可能,包括干细胞或循环肿瘤细胞,以便进一步分析。此外,它使纯化特定的细胞类型更容易,用于治疗,如开发基于细胞的药物或研究免疫细胞群。
然而,设备的高成本、严格的法规、熟练人员的缺乏以及发展中国家对细胞分拣技术的认识不足是阻碍细胞分拣市场增长的一些因素。
近60%的美国成年人患有至少一种慢性疾病。美国的主要死因包括糖尿病、癌症和心血管疾病等慢性疾病。心脏病、癌症、中风、慢性阻塞性肺病和糖尿病占所有死亡人数的三分之二以上。
根据CDC的数据,全国每年3.8万亿美元的医疗费用中,有90%是由慢性病患者和精神健康问题引起的。根据对抗慢性病伙伴关系最近的一份报告,到2030年,美国治疗七种最流行的慢性病的费用每年将达到2万亿美元,或每人8,600美元。根据同一份报告,减少有害行为可能每年防止110万人死亡。
美国最大的产业之一是生物制药,每年价值数十亿美元,对美国经济和使用其产品的病人至关重要。由于CDMO生物制品公司的出现,这项业务正在经历巨大的扩张,这些公司比以前更快地产生药品。
这个行业的扩张也归因于世界人口的扩大。世界人口的需求增加了生物制药企业的压力,但也让它吸引了更多的投资,提高了利润率,并进行了扩张。
有了个性化医疗,就有可能将 "一刀切 "的诊断、用药和预防方法转变为个性化的方法。根据病人的独特特征进行有针对性的治疗是个性化医疗的目标。识别和分离特定的细胞类型以进行定制治疗,在很大程度上取决于细胞分拣技术。随着个性化医疗的发展,对细胞分选技术的需求预计将上升。
COVID-19大流行病对细胞分拣市场产生了积极影响。免疫反应的变异性和COVID-19对各种细胞类型的影响已经利用单细胞分析技术(包括细胞分选)进行了广泛的研究。这场大流行加强了单细胞分析技术,并通过强调理解单个细胞的特征和反应的需要而增加了对细胞分拣技术的需求。
俄乌战争对细胞分拣市场的影响是复杂和多面的。用于在受影响地区建设医疗基础设施的资源、注意力和资金可能会被冲突及其后果所转移。这可能会影响尖端技术,如细胞分拣,在医疗保健和研究背景下的采用和使用。
The Global Cell Sorting Market reached US$ 236.5 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 389.8 million by 2030. The Global Cell Sorting Market is expected to exhibit a CAGR of 6.6% during the forecast period 2023-2030.
Cell sorting has numerous applications in research, clinical diagnostics, and therapeutics. It makes it possible to separate rare cell groups, including stem cells or circulating tumor cells, for further analysis. Additionally, it makes it easier to purify particular cell types for therapeutic uses like developing cell-based medicines or researching immune cell populations.
However, the high cost of devices, stringent regulations, lack of skilled personnel and lack of awareness of cell sorting technology in developing countries are some factors hindering the growth of the cell sorting market.
Nearly 60% of American adults suffer from at least one chronic illness. The major causes of death in the US include chronic diseases like diabetes, cancer, and cardiovascular disease. Heart disease, cancer, stroke, chronic obstructive pulmonary disease, and diabetes account for over two-thirds of all fatalities.
According to the CDC, 90% of the nation's $3.8 trillion in annual healthcare costs are attributable to persons with chronic illnesses and mental health issues. According to a recent report by the Partnership to Fight Chronic Disease, by 2030, the expense of treating the seven most prevalent chronic diseases in the United States will total $2 trillion annually or $8,600 per person. According to the same report, reducing harmful behaviors might prevent 1,100,000 deaths annually.
One of the largest industries in America is biopharma, which is worth billions of dollars annually and is crucial to the American economy and the patients who use their products. This business is experiencing tremendous expansion due to the emergence of CDMO Biologics companies, which are generating pharmaceuticals more quickly than before.
The expansion of this industry is also attributed to an expanding world population. The demand from the world's population has increased pressure on the biopharma business, but it has also allowed it to attract more investment, increase profitability, and expand.
With personalized medicine, it's possible to transform a "one size fits all" approach to diagnosis, medication, and prevention into an individualized one. Targeted treatments based on unique patient traits are the goal of personalized medicine. Identifying and isolating particular cell types for customized therapeutics depend heavily on cell sorting technology. The demand for cell sorting technology is anticipated to rise as personalized medicine grows.
The COVID-19 pandemic has had a positive impact on the cell sorting market. The variability of the immune response and the effects of COVID-19 on various cell types have been extensively studied using single-cell analytic techniques, including cell sorting. The pandemic has enhanced single-cell analysis techniques and increased demand for cell sorting technology by highlighting the need to comprehend individual cells' traits and reactions.
The impact of the Russia-Ukraine war on the cell sorting market is complex and multifaceted. Resources, attention, and finance for the construction of healthcare infrastructure in the impacted areas may be diverted by the conflict and its aftermath. This might affect how cutting-edge technologies, like cell sorting, are adopted and used in healthcare and research contexts.
The Global Cell Sorting Market is segmented based on technology, product and services, application, End-user, and region.
The fluorescence-activated cell sorting (FACS) segment accounted for the highest market stake, accounting for approximately 43.6% of the cell sorting market in 2022. The flow cytometry technique, fluorescence-activated cell sorting (FACS), is specialized. Using the unique light scattering and fluorescence properties of each cell, it offers a way for dividing a heterogeneous mixture of living cells into two or more containers, one cell at a time.
It is a practical scientific tool since it allows for the quick, accurate, and quantitative recording of fluorescence signals from individual cells as well as the physical segregation of cells of specific interest.
North America is expected to dominate the cell sorting market, accounting for around 39.6%. The market player applies strategies such as product launches and collaboration to expand their business.
For instance, in January 2023, Thermo Fisher Scientific, the leader in serving science, launched the Bigfoot Spectral Cell Sorter in India. The groundbreaking cell sorting system combines spectral sorting and analysis with traditional sorting to produce quick, simple-to-use cell sorting.
The major global players in the market include: Bio-Rad Laboratories, Inc., Sony Biotechnology Inc., BD, Merck KGaA, Danaher Corporation, Miltenyi Biotec GmbH, Affymetrix, Inc., Sysmex Partec GmbH, On-Chip Biotechnologies Co., Ltd., Thermo Fisher Scientific among others.
The Global Cell Sorting Market Report Would Provide Approximately 69 Tables, 70 Figures And 195 pages.
LIST NOT EXHAUSTIVE